Health Care Professionals in Europe May Recommend Actos When All Other Options Have Failed

Ennis & Ennis, P.A. Explains Actos is Essentially a “Last Ditch Effort” Medication in Europe Due to Its Risk of Bladder Cancer (PRWEB) October 26, 2011 On October 21, 2011, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) clarified its opinion on pioglitazone-containing anti-diabetes medications, such as Actos, and the risk of bladder cancer on the request of the European Commission. According to Ennis & Ennis, P.A., the Committee reported that due to the bladder cancer risk posed by pioglitazone, which is the sole ingredient in Actos, the
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations